

Table 1: Summary of L-ASP pharmacology experiments

| Cell Line | Mean EC₅₀ (U/mL) | 95% Confidence Interval | Type |
|-------------------|--|------------------------------------|---------------------------------|
| 222 | 1.61 | 1.21 to 2.12 | endometrioid adenocarcinoma |
| A224 | 0.36 | 0.33 to 0.39 | papillary serous adenocarcinoma |
| A2780 | 0.22 | 0.20 to 0.24 | papillary serous adenocarcinoma |
| A364 | 0.25 | 0.22 to 0.29 | papillary serous adenocarcinoma |
| A547 | 0.19 | 0.11 to 0.34 | papillary serous adenocarcinoma |
| AD10 | 0.24 | 0.22 to 0.27 | papillary serous adenocarcinoma |
| CaOV3 | 5.04 | 3.77 to 6.74 | papillary serous adenocarcinoma |
| IGROV1 (NCI) | 1.10 | 0.45 to 2.67 | adenocarcinoma |
| OVCAR-3 (NCI) | 1.19 | 0.94 to 1.50 | adenocarcinoma |
| OVCAR-3 | 0.86 | 0.56 to 1.32 | papillary serous adenocarcinoma |
| OVCAR-4 (NCI) | 5.48 | 4.27 to 7.02 | adenocarcinoma |
| OVCAR420 | 0.30 | 0.21 to 0.42 | adenocarcinoma |
| OVCAR429 | 0.40 | 0.28 to 0.58 | serous cystadenocarcinoma |
| OVCAR432 | 0.29 | 0.23 to 0.36 | adenocarcinoma |
| OVCAR-8 (NCI) | 0.49 | 0.44 to 0.53 | adenocarcinoma |
| OVCAR-8/ADR (NCI) | 0.20 | 0.17 to 0.23 | adenocarcinoma |
| SKOV3 (NCI) | 0.18 | 0.10 to 0.31 | papillary serous adenocarcinoma |
| SKOV3 | 0.29 | 0.25 to 0.33 | papillary serous adenocarcinoma |
| UCI101 | 7.71 | 1 to 82 | papillary serous adenocarcinoma |